215 related articles for article (PubMed ID: 16931569)
1. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C.
Ngo Y; Munteanu M; Messous D; Charlotte F; Imbert-Bismut F; Thabut D; Lebray P; Thibault V; Benhamou Y; Moussalli J; Ratziu V; Poynard T
Clin Chem; 2006 Oct; 52(10):1887-96. PubMed ID: 16931569
[TBL] [Abstract][Full Text] [Related]
2. Fibrotest-Actitest: the biochemical marker of liver fibrosis--the Israeli experience.
Morali G; Maor Y; Klar R; Braun M; Ben Ari Z; Bujanover Y; Zuckerman E; Boger S; Halfon P
Isr Med Assoc J; 2007 Aug; 9(8):588-91. PubMed ID: 17877064
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease.
Ratziu V; Massard J; Charlotte F; Messous D; Imbert-Bismut F; Bonyhay L; Tahiri M; Munteanu M; Thabut D; Cadranel JF; Le Bail B; de Ledinghen V; Poynard T; ;
BMC Gastroenterol; 2006 Feb; 6():6. PubMed ID: 16503961
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C.
Vergniol J; Foucher J; Terrebonne E; Bernard PH; le Bail B; Merrouche W; Couzigou P; de Ledinghen V
Gastroenterology; 2011 Jun; 140(7):1970-9, 1979.e1-3. PubMed ID: 21376047
[TBL] [Abstract][Full Text] [Related]
5. Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study.
Halfon P; Bourliere M; Deydier R; Botta-Fridlund D; Renou C; Tran A; Portal I; Allemand I; Bertrand JJ; Rosenthal-Allieri A; Rotily M; Sattonet C; Benderitter T; Saint Paul MC; Bonnot HP; Penaranda G; Degott C; Masseyeff MF; Ouzan D
Am J Gastroenterol; 2006 Mar; 101(3):547-55. PubMed ID: 16542291
[TBL] [Abstract][Full Text] [Related]
6. Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies.
Bourliere M; Penaranda G; Renou C; Botta-Fridlund D; Tran A; Portal I; Lecomte L; Castellani P; Rosenthal-Allieri MA; Gerolami R; Ouzan D; Deydier R; Degott C; Halfon P
J Viral Hepat; 2006 Oct; 13(10):659-70. PubMed ID: 16970597
[TBL] [Abstract][Full Text] [Related]
7. The FibroTest value in discriminating between insignificant and significant fibrosis in chronic hepatitis C patients. The Romanian experience.
Grigorescu M; Rusu M; Neculoiu D; Radu C; Serban A; Catanas M; Grigorescu MD
J Gastrointestin Liver Dis; 2007 Mar; 16(1):31-7. PubMed ID: 17410286
[TBL] [Abstract][Full Text] [Related]
8. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study.
Imbert-Bismut F; Ratziu V; Pieroni L; Charlotte F; Benhamou Y; Poynard T;
Lancet; 2001 Apr; 357(9262):1069-75. PubMed ID: 11297957
[TBL] [Abstract][Full Text] [Related]
9. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy.
Shaheen AA; Wan AF; Myers RP
Am J Gastroenterol; 2007 Nov; 102(11):2589-600. PubMed ID: 17850410
[TBL] [Abstract][Full Text] [Related]
10. Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver Biopsy.
Schmid P; Bregenzer A; Huber M; Rauch A; Jochum W; Müllhaupt B; Vernazza P; Opravil M; Weber R;
PLoS One; 2015; 10(9):e0138838. PubMed ID: 26418061
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease.
Naveau S; Gaudé G; Asnacios A; Agostini H; Abella A; Barri-Ova N; Dauvois B; Prévot S; Ngo Y; Munteanu M; Balian A; Njiké-Nakseu M; Perlemuter G; Poynard T
Hepatology; 2009 Jan; 49(1):97-105. PubMed ID: 19053048
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Fibrotest and PGAA for the diagnosis of fibrosis stage in patients with alcoholic liver disease.
Naveau S; Essoh BM; Ghinoiu M; Marthey L; Njiké-Nakseu M; Balian A; Lachgar M; Prévot S; Perlemuter G
Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):404-11. PubMed ID: 24561990
[TBL] [Abstract][Full Text] [Related]
13. Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population.
Poynard T; Munteanu M; Deckmyn O; Ngo Y; Drane F; Castille JM; Housset C; Ratziu V; Imbert-Bismut F
J Hepatol; 2012 Sep; 57(3):541-8. PubMed ID: 22612998
[TBL] [Abstract][Full Text] [Related]
14. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients.
Myers RP; Benhamou Y; Imbert-Bismut F; Thibault V; Bochet M; Charlotte F; Ratziu V; Bricaire F; Katlama C; Poynard T
AIDS; 2003 Mar; 17(5):721-5. PubMed ID: 12646795
[TBL] [Abstract][Full Text] [Related]
15. Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration.
Castera L; Winnock M; Pambrun E; Paradis V; Perez P; Loko MA; Asselineau J; Dabis F; Degos F; Salmon D
HIV Med; 2014 Jan; 15(1):30-9. PubMed ID: 24007567
[TBL] [Abstract][Full Text] [Related]
16. Liver fibrosis in young Egyptian beta-thalassemia major patients: relation to hepatitis C virus and compliance with chelation.
Elalfy MS; Esmat G; Matter RM; Abdel Aziz HE; Massoud WA
Ann Hepatol; 2013; 12(1):54-61. PubMed ID: 23293194
[TBL] [Abstract][Full Text] [Related]
17. Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C.
Sebastiani G; Halfon P; Castera L; Mangia A; Di Marco V; Pirisi M; Voiculescu M; Bourliere M; Alberti A
Aliment Pharmacol Ther; 2012 Jan; 35(1):92-104. PubMed ID: 22035045
[TBL] [Abstract][Full Text] [Related]
18. FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis.
Salkic NN; Jovanovic P; Hauser G; Brcic M
Am J Gastroenterol; 2014 Jun; 109(6):796-809. PubMed ID: 24535095
[TBL] [Abstract][Full Text] [Related]
19. Correlation between liver biopsy and fibrotest in the evaluation of hepatic fibrosis in patients with chronic hepatitis C.
Said Y; Salem M; Mouelhi L; Mekki H; Houissa F; Ben Rejeb M; Moussa A; Trabelsi S; Debbeche R; Bouzaidi S; Najjar T
Tunis Med; 2010 Aug; 88(8):573-8. PubMed ID: 20711964
[TBL] [Abstract][Full Text] [Related]
20. Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors.
Imbert-Bismut F; Messous D; Thibault V; Myers RB; Piton A; Thabut D; Devers L; Hainque B; Mercadier A; Poynard T
Clin Chem Lab Med; 2004 Mar; 42(3):323-33. PubMed ID: 15080567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
